

07/05/01
U.S. PTO
JULY 200107-06-01
A

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	<i>Title of Invention</i>	Estrogenic Compounds as Antiangiogenic Agents
	<i>Named Inventor(s)</i>	Robert J. D'Amato, Ravi K. Varma, Rudiger G. Haugwitz and Mark Cushman
	<i>Attorney Docket</i>	05213-0910 (43170-219505)
	<i>Express Mail Label No.</i>	EL910716395US

J-1046 U.S. PTO
09/899702

07/05/01

APPLICATION ELEMENTS		ACCOMPANYING APPLICATION PARTS
<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Applicant claims Small Entity status</p> <p>3. <input checked="" type="checkbox"/> Specification, Claims, and Abstract Total Pages 29</p> <p>4. <input checked="" type="checkbox"/> Drawings Total Sheets 4 Total Pages 33</p> <p>5. Oath or Declaration</p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input checked="" type="checkbox"/> Copy from prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 16 completed) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p> <p>(i) <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p>		<p>7. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)</p> <p>a. <input type="checkbox"/> Computer Readable Copy</p> <p>b. <input type="checkbox"/> Paper Copy (identical to computer copy)</p> <p>c. <input type="checkbox"/> Statement verifying identity of above copies</p> <p>8. <input checked="" type="checkbox"/> Assignment:</p> <p>a. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))</p> <p>b. <input checked="" type="checkbox"/> Assignment is of record in parent application No. 09/154,322</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee)</p> <p><input type="checkbox"/> Power of Attorney by assignee</p> <p>10. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>11. <input type="checkbox"/> Information Disclosure Statement (IDS) PTO-1449</p> <p><input type="checkbox"/> Copies of IDS Citations</p> <p>12. <input type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</p> <p>14. <input type="checkbox"/> Certified Copy of Priority Document(s)</p> <p>15. <input checked="" type="checkbox"/> Other: Ck. \$427.00; copy of 3 month extension of time from parent case 09/154,322</p>
<p>16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:</p> <p><input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: 09/154,322 Recite complete dependency back to first parent application: This is a continuation of prior application number 09/154,322, filed September 16, 1998, which claims priority to U.S. Provisional application serial number 60/059,916, filed September 24, 1997.</p> <p>17. CORRESPONDENCE ADDRESS:</p> <p>KILPATRICK STOCKTON LLP Attn: John S. Pratt Suite 2800 1100 Peachtree Street Atlanta, Georgia 30309-4530</p> <p>By: <u>Suzanne Seavello Shope</u> Reg. No. 37,933 Suzanne Seavello Shope Date: July 5, 2001 Telephone: 404-815-6500 Facsimile: 404-815-6555</p>		

FEE TRANSMITTALAttorney Docket No. **05213-0910 (43170-219505)**

This sheet accompanies a patent application transmittal for the following application:

Inventor(s): **Robert J. D'Amato, Ravi K. Varma, Rudiger G. Haugwitz, and Mark Cushman**
Filing Date: **July 5, 2001**
Title: **Estrogenic Compounds as Antiangiogenic Agents**

The filing fee is calculated as shown below:

1. FILING FEE:

FOR:	SMALL ENTITY		LARGE ENTITY	
	FEE	FEE PAID	FEE	FEE PAID
<input checked="" type="checkbox"/> UTILITY FILING FEE	\$355	355	\$710	
<input type="checkbox"/> DESIGN FILING FEE	\$160		\$320	
<input type="checkbox"/> PLANT FILING FEE	\$245		\$490	
<input type="checkbox"/> REISSUE FILING FEE	\$355		\$710	
<input type="checkbox"/> PROVISIONAL FILING FEE	\$75		\$150	
	SUBTOTAL (1)	\$355		\$

2. CLAIMS:

FOR:	SMALL ENTITY		LARGE ENTITY	
	NO. FILED	NO. EXTRA	RATE	FEE
TOTAL CLAIMS	28 - 20 =	8	x 9 =	72
INDEP. CLAIMS	2 - 3 =	0	x 40 =	x 80 =
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED		+135 =		+270 =
	SUBTOTAL (2)		\$72	\$

3. ADDITIONAL FEES:

FOR:	SMALL ENTITY		LARGE ENTITY	
	FEE	FEE PAID	FEE	FEE PAID
<input type="checkbox"/> LATE FILING, FEE OR OATH	\$65		\$130	
<input type="checkbox"/> NON-ENGLISH SPECIFICATION	\$130		\$130	
<input type="checkbox"/> OTHER				
	SUBTOTAL (3)	\$427.00		\$

TOTAL FILING FEES: \$427.00A check is enclosed for the total amount: **\$427.00** Charge any additional fees required under 37 C.F.R. 1.16 or 1.17 to Deposit Account 11-0855.

KILPATRICK STOCKTON LLP
Suite 2800
1100 Peachtree Street
Atlanta, Georgia 30309-4530
Telephone: 404-815-6500

By: Suzanne Seavello Shope Date: 7/15/01
Suzanne Seavello Shope, Attorney for Applicant
Reg. No. 37,933